These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39217072)

  • 1. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
    Fotia G; Saieva C; Lee-Ying R; Patrikidou A; Nuzzo PV; Zanardi E; Rossetti S; Davidsohn M; Eid M; El Zarif T; McClure H; Spinelli GP; Damassi A; Murianni V; Vauchier C; Oliveira TM; Malgeri A; Modesti M; Mestre RP; Valenca L; Ravi P; Santini D; Pignata S; De Giorgi U; Sweeney C; Heng D; Procopio G; Russo A; Francini E;
    Clin Genitourin Cancer; 2024 Oct; 22(5):102185. PubMed ID: 39217072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
    Nuzzo PV; Pederzoli F; Saieva C; Zanardi E; Fotia G; Malgeri A; Rossetti S; Valenca Bueno L; Andrade LMQS; Patrikidou A; Mestre RP; Modesti M; Pignata S; Procopio G; Fornarini G; De Giorgi U; Russo A; Francini E;
    J Transl Med; 2023 Feb; 21(1):75. PubMed ID: 36737752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
    Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
    Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study.
    Bahl A; Sodatonou H; Snjider R; Chilelli A; Pranzo A; Martins K; Merseburger A; Rozario N; Crawley D
    World J Urol; 2024 Oct; 42(1):584. PubMed ID: 39422767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Watanabe H; Nakane K; Takahara K; Naiki T; Yasui T; Shiroki R; Koie T; Miyake H
    Int J Urol; 2024 Sep; 31(9):986-993. PubMed ID: 38764245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).
    Shore ND; Saltzstein D; Sieber P; Mehlhaff B; Gervasi L; Phillips J; Wong YN; Pei H; McGowan T
    Clin Genitourin Cancer; 2019 Dec; 17(6):457-463.e6. PubMed ID: 31473120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
    Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Di Stefano RF; Tucci M; Turco F; Samuelly A; Bungaro M; Pisano C; Vignani F; Gallicchio M; Scagliotti GV; Di Maio M; Buttigliero C
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):812-825. PubMed ID: 33603237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
    Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
    Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.